Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...
Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
Everyday Health on MSN
SGLT2 inhibitors and IgAN: Can this diabetes drug delay kidney decline?
Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.
STOCKHOLM — In the treatment of type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) show independent benefits that complement ...
MedPage Today on MSN
Prior Biologic Use Tied to JAK Inhibitor Benefit in Ulcerative Colitis
In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results